Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.

The NK1 receptor antagonist serlopitant for treatment of chronic pruritus

Open access
Ständer, Sonja, Spellman, Mary C., Kwon, Paul, Yosipovitch, Gil · 2019 · Expert Opinion on Investigational Drugs

Abstract

Introduction: Pruritus is a common symptom associated with several potential underlying causes, including both dermatologic and systemic diseases; it can also occur without an identifiable cause. Current treatment options are limited and most patients experience impaired quality of life. Serlopitant is a neurokinin 1 (NK1) receptor antagonist under development for the treatment of pruritus associated with various dermatologic conditions and chronic pruritus of unknown origin.Areas covered: This review describes the epidemiology and unmet needs of patients with chronic pruritus, focusing specifically on patients with prurigo nodularis, psoriatic itch, and chronic pruritus of unknown origin; the rationale for targeting the NK1 receptor for treatment of chronic pruritus; and the clinical development of serlopitant, including efficacy and safety data from completed phase II studies.Expert opinion: There is an unmet need for novel, safe, and effective therapies to treat chronic pruritus. Serlopitant has shown promising efficacy, safety, and tolerability across different patient populations, including adolescents and elderly patients. In contrast to less convenient administration options, serlopitant is a once-daily oral tablet, which is expected to facilitate compliance.Trial registration: ClinicalTrials.gov identifier: NCT00290563.Trial registration: ClinicalTrials.gov identifier: NCT00835718.Trial registration: ClinicalTrials.gov identifier: NCT03282591.Trial registration: ClinicalTrials.gov identifier: NCT01951274.Trial registration: ClinicalTrials.gov identifier: NCT02196324.Trial registration: ClinicalTrials.gov identifier: NCT02975206.Trial registration: ClinicalTrials.gov identifier: NCT03343639.Trial registration: ClinicalTrials.gov identifier: NCT03546816.Trial registration: ClinicalTrials.gov identifier: NCT03677401.Trial registration: ClinicalTrials.gov identifier: NCT03540160.Trial registration: ClinicalTrials.gov identifier: NCT03841331.

Overview

Integrity signals

Registry

Crossref · 10.1080/13543784.2019.1638910

Cites

45 of 45 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 45 references

Research works printed but not linked: 3

  1. Saco M, 2015, J Fam Pract, 64, 221
  2. Andoh T, 1998, J Pharmacol Exp Ther, 286, 1140
  3. 2019, Data on file

Cited by

See all 26

Metadata

Authors
Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G.
Affiliations
  • University Hospital Münster (DE)
  • Vyne Therapeutics (United States) (US)
  • University of Miami (US)
Corresponding author
Ständer, Sonja
Venue
Expert Opinion on Investigational Drugs
Published
2019-07-04
Volume
28
Issue
8
Pages
659-666
ISSN
  • 1354-3784 (ISSN-L)
  • 1744-7658
OpenAlex
W2954505358
Cited by
26
References
45
Citations by year
2026: 2 · 2025: 4 · 2024: 1 · 2023: 5 · 2022: 2 · 2021: 7 · 2020: 5
FWCI
3.51
Type
journal article
Language
en
Open access
Locations
  • Expert Opinion on Investigational Drugs (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
Menlo Therapeutics (NA)
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Dermatology › Urticaria and Related Conditions
  • Health Sciences › Medicine › Physiology (medical) › Pain Mechanisms and Treatments
Keywords
chronic pruritus, NK1 receptor antagonists, prurigo nodularis, drug development, treatment efficacy and safety, unmet medical needs, quality of life
MeSH terms
Animals, Antipruritics, Chronic Disease, Humans, Pruritus, Quality of Life, Receptors, Neurokinin-1, Isoindoles, Neurokinin-1 Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. https://app.cochat.ai/papers/10.1080/13543784.2019.1638910
The paper
Ständer, S., Spellman, M. C., Kwon, P., & Yosipovitch, G. (2019). The NK1 receptor antagonist serlopitant for treatment of chronic pruritus. Expert Opinion on Investigational Drugs. https://doi.org/10.1080/13543784.2019.1638910

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.